Top Back to top

MDS ATG versus Post-Cy in unrelated donors

Chronic Malignancies Working Party (CMWP)
Type d'étude:
Numéro de l'étude:
42205675
Type de traitement à base de cellules souches:
Allogeneic - Unrelated
Maladies:
Myelodysplastic (MDS) or MDS/MPN
Titre court:
 
Objectif principal:
The objective of the study is to evaluate the outcome of patients with MDS who underwent allogeneic HSCT and received GvHD prophylaxis with cyclophosphamide post-transplantation compared to those who received Antithymocyte Globulin (ATG).
The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
Principaux critères d'inclusion:
o Diagnosis of MDS or MDS transformed to AML before first allogeneic HSCT.
o Adults (≥18 years) at time of transplantation.
o First allogeneic HSCT between 2012-2019.
o Stem cell source: bone marrow or peripheral blood from an unrelated donor.
o Post-cyclophosphamide (post-CY) as GvHD prophylaxis or Antithymocyte Globulin (ATG) as conditioning or GvHD prophylaxis treatment.
Pays:
 
Investigateur principal:
Yves Chalandon, Marie Robin
Coordinateur EBMT de l'étude:
Laurien Baaij
E-mail du coordinateur de l'étude:
cmwpebmt@lumc.nl